MedTrace Logo

PRF in Management of Chronic Multiple Oral Ulcers

NCT03878771 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 804

Last updated 2020-09-07

No results posted yet for this study

Summary

PRF in orabase will be applied as a pack material on chronic oral ulcers of chronic multiple oral lesions compared to conventional topical steroid therapy with clobetasol propionate 0.05% in orabase. The outcomes measured are Pain alleviation as Primary outcome and Clinical improvement in terms of Ulcer size, Number and Mucositis score as Secondary outcomes. Time frame for outcomes assessment will be Daily for 7 Days regarding pain score and weekly for 2 weeks regarding clinical improvement.

Conditions

  • Oral Ulcer Due to Pemphius Vularis
  • Oral Ulcer Due to Benign Mucous Membrane Pemphioid
  • Oral Ulcer Due to Steven Johnson's Syndrome

Interventions

BIOLOGICAL

Platelet rich fibrin gel in Orabase

applied on oral mucositis and /or ulcer 3 times per day

DRUG

Dermovate cream in Orabase

applied on oral mucositis and /or ulcer 3 times per day

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-13
Primary Completion
2019-04-15
Completion
2019-04-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03878771 on ClinicalTrials.gov